A private investor briefing will be held in Sydney to provide an update on portfolio deployment, pipeline and fund positioning.
* Thursday, 5 March
* 6:00pm AEDT (arrival from 5:30pm)
* Sydney CBD (venue shared with approved attendees)
The session will include updates from the VentureCrowd and Sydney Angels teams, along with selected portfolio founders.
Attendance is limited to wholesale investors and financial advisers.
Further details: CLICK HERE
Sydney Angels Portfolio Update: CrossCourtAI Joins Startmate Summer’26 Cohort
Sydney Angels notes that portfolio company CrossCourtAI has been accepted into the Startmate Summer’26 Accelerator Cohort, joining 19 companies and 42 founders selected across Australia and New Zealand.
CrossCourtAI delivers AI-driven investment screening and quarterly reporting for institutional real estate and private credit firms. Its platform, Harper, generates investment papers, financial models and asset updates in minutes, enabling investment teams to focus on analysis and decision-making.
The company was founded by Sai Naicker (ex-J.P. Morgan, Barrenjoey, Cerberus Capital), James Oliver (ex-V-DAQ), and Randula Ariyawanse (ex-Optiver).
Sydney Angels Portfolio Company - SafeGauge
Aussie ingenuity saving lives! Definitely worth a closer look!
Sydney Angels Portfolio Update: ezyCollect Acquisition
ezyCollect, a Sydney Angels portfolio company, has been acquired by Sidetrade in a transaction valuing the business at A$66.5 million.
Founded in 2014, ezyCollect built an AI-powered accounts receivable platform serving more than 1,200 customers globally and generating approximately $15 million in SaaS revenue. The acquisition provides Sidetrade with a strategic entry into the Asia-Pacific market while enabling ezyCollect to continue operating with local leadership supported by global scale.
For early investors in the 2016 Sydney Angels syndicate, the transaction represents a significant liquidity event.
Beyond the pitch: The changing face of angel investment
Sydney Angels participated in a recent study looking into the role of angel investment groups in capital allocation for start-ups with Jo-Ann Suchard Associate Professor at UNSW Business School. There are some interesting insights, check it out !
Sydney Angels Sidecar Fund 3 Makes Its First Investment in iiShield
Exciting to see Sydney Angels Sidecar Fund 3 make its first investment into iiShield an exciting milestone for both investors and founders in the startup space.
The Future of Investing: Accessing High-Growth Private Companies Early
“The highest-growth companies in the world are private but by the time they appear in the AFR, it’s too late." — Adrian Bunter, Investment Committee Member, Sydney Angels
Spark Festival 2026!
🌟 Join Sydney Angels at Spark Festival 2025! 🌟
We’re thrilled to be part of this year’s Spark Festival, and we’d love for you to join us!
💡 Two online workshops not to miss:
📅 Tuesday, 28 October | 1:00–2:00pm
🎙️ Demystifying Term Sheets with Richard Dale
🔗 Register: https://lnkd.in/gUu36hCE
📅 Friday, 31 October | 12:00–1:00pm
🎙️ Angel Investing 101 with Philip Argy
🔗 Register: https://lnkd.in/gGV6xFRr
These sessions are free and open to the public - so tag a friend, colleague, or founder who’d love to learn more about startup investing and join the conversation.
Sydney Angels Leads Mary Technology Investment Rounds
Sydney Angels is excited to have been able to lead Mary Technology's investment rounds.
It is amazing to see the impact Mary is having.
Sydney Angels on the Global Stage at BIO Boston
Great to see Sydney Angels get a mention during the BIO International Convention in Boston last week, where our committee member Rob McInnes spoke on early-stage biotech investing.
It’s always valuable to have members like Rob representing the angel investing perspective on global stages.
Sydney Angels - The Process, and the SASF3 - Funded Futures Podcast with Adrian Bunter
More than just another angel group.
Sydney Angels Portfolio Company: Clarity Pharmaceuticals - Highlights from the Quarter
Clarity achieved in the last quarter and our plans for future development as we continue to move closer to our ultimate goal of improving treatment outcomes for children and adults with cancer.
Sydney Angels Sidecar Fund 3 Launch!
Thank you Adrian and Philip, two of our elected Committee Members, who have been working hard for months to launch Sydney Angels Sidecar Fund 3, in partnership with VentureCrowd.
Sydney Angels Portfolio Company - Seitec
An exciting update from Seitec: technical risk has now been retired and the team has successfully moved into a T&E program for their market-entry platform.
Sydney Angels Portfolio Company - SafeGauge
Enhance testing precision with the SafeGauge Dial Indicator and MultiTool Pro. Conduct Snap Checks on Letourneau loader pins, identify rapid movements with 64 samples per second, and automatically calculate snap movements with the 'Points' feature.
Sydney Angels Portfolio Company - Okkular.io - Let's Optimise Smarter!
AI-driven automation makes it seamless! Okkular’s AI solutions generate rich, structured, and scalable product information, ensuring accuracy and consistency across your fashion product catalogues
The result? Customers have the right product details at their fingertips, shop with confidence, and brands see better engagement, higher sales, and fewer abandoned carts.
Sydney Angels Portfolio Company - Clarity Pharmaceuticals - Focus on Theranostics
Watch this insightful panel discussion "Theranostics in Focus: New Frontiers in Cancer Care" with Global Key Opinion Leaders, Professor Louise Emmett and Professor Oliver Sartor, and our Executive Chairperson, Dr Alan Taylor, as they discuss how this new area of theranostics is transforming cancer care, the pivotal role of industry-academic partnerships in shaping this change, as well as the unique benefits and challenges to be overcome, hosted by A/Prof Sophie Scott OAM at St Vincent's, Sydney.
Sydney Angels Portfolio Company - Clarity Pharmaceuticals
Clarity is thrilled to announce that the first patient with metastatic prostate cancer to receive 2 doses of 8GBq of Cu-67 SAR-bisPSMA achieves undetectable PSA level. The patient was heavily pre-treated with multiple lines of therapy, including androgen deprivation therapy, ARPI, chemotherapy and a PARP inhibitor and had failed all previous treatments.
Sydney Angels Portfolio Company - Safe-Gauge
As 2023 comes to a close, let's raise a toast to the exceptional journey we've had at SafeGauge. From major expos and prestigious awards to groundbreaking collaborations and product launches, it's been a year filled with achievements and milestones.
None of this would have been possible without your invaluable support. To our incredible customers, partners, and friends, thank you for being a vital part of SafeGauge's success in 2023. Looking forward to reaching new heights together in the coming year.
Sydney Angels Portfolio Company - NOA The Brand
It’s been a big year for us, and no better way to wrap it up than receiving news that NOA The Brand has been accepted into the Startmate Accelerator’s Summer ’24 cohort! 🎉
We are beyond excited to see what the next 12 weeks holds for us and look forward to heading to Melbourne in mid January. Can’t wait to take NOA The Brand to the next level with the Startmate team and their sensational mentor community! 🚀
Until then, we're taking a much needed break and will be back in action in early January. Have a safe and happy holiday break!
